Histamine dihydrochloride and low-dose interleukin-2 has anti-leukemic efficacy in NPM1-mutated and myelomonocytic/monocytic acute myeloid leukemia

by Malin S. Nilsson, Michael Fiegl, Wolfgang Hiddemann, Wolfgang R. Sperr, Fredrik B. Thorén, Anna Martner, and Kristoffer Hellstrand

Received: March 22, 2024.
Accepted: June 13, 2024.


Publisher’s Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in a regular issue of the journal.
All legal disclaimers that apply to the journal also pertain to this production process.
Histamine dihydrochloride and low-dose interleukin-2 has anti-leukemic efficacy in NPM1-mutated and myelomonocytic/monocytic acute myeloid leukemia

Malin S. Nilsson¹,², Michael Fieg³, Wolfgang Hiddemann⁴, Wolfgang R. Sperr⁵,⁶, Fredrik B. Thorén¹,⁷, Anna Martner¹,², Kristoffer Hellstrand¹,⁸

¹TIMM laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden
²Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
³Internal Medicine, Privatklinik Hochrum, Rum, Austria
⁴Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany
⁵Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁶Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
⁷Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
⁸Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence:
Kristoffer Hellstrand
ORCID ID: 0000-0002-6617-5976
Medicinaregatan 1F, 41390 Gothenburg, Sweden
email: kristoffer.hellstrand@microbio.gu.se
Disclosures

Author MF is a consultant to Bristol-Myers Squibb, AbbVie and Otsuka. Author WH reports research funding from F. Hoffmann-La Roche Ltd, Janssen and Bayer. Author WRS has received honoraria, scientific grants or travel support from AbbVie, Astellas, Blueprint, BMS-Celgene, Daiichi Sankyo, Deciphera, Incyte, Jazz, Laboratoires Delbert, Novartis, Otsuka, Pfizer, Servier, StemLine, and Thermo Fisher. Author KH is a consultant to Laboratories Delbert. Authors FBT, AM and KH have authored pending patents protecting NOX2 inhibitors as immunotherapy in cancer.

Author contributions

MF, WH and WRS participated in designing and performing the study. MSN, FBT, AM and KH compiled and analyzed results and drafted a first manuscript version. All authors participated in writing the final manuscript.

Acknowledgments

The authors are grateful to participating patients and clinicians and to Dr Ursula Petzold, Dr Hans Christian Kuhl and Prof Staffan Nilsson.

Funding

The study was supported by MEDA Pharma GmbH & Co. Authors FBT, AM and KH have research grants from the Swedish Cancer Society (22 2388 Pj (FBT), 22 2128 Pj (AM), and 21 1864 Pj (KH)) and the Swedish state via the ALF agreement (ALFGBG-963642 (FBT), ALFGBG-724881 (AM) and ALFGBG-718421 (KH)). FBT and AM have grants from the Swedish Research Council (2020-02783 (FBT) and 2023-02193 (AM)).

Data-sharing statement

Data used to support the findings of the registry study are available from the corresponding author upon request.
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) has been reported to reduce the risk of relapse in younger adults with acute myeloid leukemia (AML)\textsuperscript{1}, but the benefit of HDC/IL-2 in molecular subgroups of AML is not known. This study reports analyses of minimal/measurable residual disease (MRD)\textsuperscript{2} in serial bone marrow (BM) and peripheral blood (PB) samples of patients with $NPM1$-mutated or core binding factor (CBF) AML. Data from a registry comprising patients who received immunotherapy with HDC/IL-2 in the post-consolidation phase were compared with outcomes of matched contemporary patients in German-Austrian registries. Results point towards reduction of molecular relapse among HDC/IL-2-treated patients with leukemic cells of monocytic origin and carrying $NPM1$ mutations.

Patients with AML frequently attain morphological disappearance of leukemic cells and restored normal hematopoiesis (defined as complete remission, CR)\textsuperscript{2} after initial induction chemotherapy. Despite ensuing cycles of consolidation and/or maintenance chemotherapy, hematological relapses in CR are common with high mortality.\textsuperscript{3} Patients at high or intermediate risk of relapse may benefit from allogeneic stem cell transplantation (allo-SCT) in the early phase of treatment\textsuperscript{4} but upfront allo-SCT is mostly not practiced in patients at lower relapse risk, including $NPM1$-mutated or CBF-AML (carrying $CBFB-MYH11$ or $RUNX1-RUNX1T1$ rearrangements). Combinatorial immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) aims to achieve immune-mediated elimination of residual leukemic cells in patients who are not eligible for allo-SCT.\textsuperscript{1} HDC/IL-2 is approved within the EU for remission maintenance with preferential efficacy in patients <60 years old.\textsuperscript{5} Post-hoc analyses of phase 3 trial results suggested pronounced relapse prevention in (i) AML of French-American-British (FAB) classes M4/M5 (myelomonocytic/monocytic AML)\textsuperscript{6}, (ii)
patients who achieve CR after the first course of chemotherapy\textsuperscript{7}, and (iii) patients with normal karyotype AML\textsuperscript{8,9}.

The past decennia have seen the implementation of molecular analysis of residual leukemia in CR for prognostication and for supporting treatment decisions. Assessment of MRD in BM or PB has proven useful to determine the efficiency of upfront chemotherapy and to detect arising or increasing leukemia in the CR phase. Here we report results from a German/Austrian registry of AML patients in first CR with $NPM1$-mutated or CBF-AML who were serially monitored for MRD before, during and after treatment with HDC/IL-2.

For comparison with outcomes among contemporary controls, matched patient data were retrieved from the AML-CG 2004 and AML-CG 2008 studies\textsuperscript{10,11}. Matching was performed by an independent party that did not have access to outcome data and included type of AML, risk group by WHO criteria, FAB class of leukemic cells and source of MRD at first analysis. A planned matching for previous chemotherapy was, however, not possible as patients treated with HDC/IL-2 had received a median of two previous cycles of intensive chemotherapy (induction and consolidation) vs. five in the matched control group (P<0.0001, t-test). Prior allo-SCT was an exclusion criterion. Quantitative assessment of the MRD markers $NPM1^{mut}$, $CBFB-MYH11$ and $RUNX1-RUNXIT1$ was performed by standardized RT-PCR. Sampling of BM and PB for MRD assessment was recommended every third month after the completion of chemotherapy. Patients (n=14) and matched controls (n=21) were MRD-negative at the end of previous chemotherapy. Patient characteristics are summarized in Table 1. The study was approved by ethical committees at participating sites\textsuperscript{9}, all patients gave written informed consent, and the study was performed according to the Declaration of Helsinki.
The primary endpoint was time from completion of previous chemotherapy to switch from MRD negativity to positivity (“molecular relapse”) in HDC/IL-2-treated patients vs. matched controls. The secondary endpoint was leukemia-free survival (LFS) where events were defined as hematological relapse or death whichever occurred first.

Sensitivity analyses included the proportion of patients with molecular relapse among all patients, in patients with \( NPM1 \)-mutated AML and in AML of FAB M4/M5 morphology. Analysis was performed in a predefined group of patients \( \leq 60 \) years old, aligning with the reported efficacy of HDC/IL-2 in reducing hematological relapse in younger patients.\(^1\) P values were calculated using the log-rank test. Patients in the registry received the same HDC/IL-2 regimen as in the phase 3 trial.\(^1\) Treatment with HDC/IL-2 was started at a median of 71 (26-122) days after the last chemotherapy and 9/14 patients completed the prescribed regimen of HDC/IL-2 with early termination of maintenance therapy mainly because of early molecular relapse. One patient in the HDC/IL-2 arm and two in the control arm proceeded to allo-SCT after molecular or hematological relapse.

We observed a trend towards reduced incidence of molecular relapse in HDC/IL-2-treated patients vs. controls (Figure 1A; \( n=35 \), \( P=0.08 \) (primary endpoint)). There were no LFS events in the HDC/IL-2 group (\( n=14 \)) vs. four LFS events (two deaths) among matched controls (\( n=21 \), \( P=0.12 \) (secondary endpoint)). All LFS events in the control arm were preceded by molecular relapse. Molecular relapse tended to be reduced by HDC/IL-2 within the group of \( NPM1 \)-mutated AML (Figure 1B; \( n=25 \), \( P=0.07 \)) and in corresponding patients with FAB class M4 or M5 (Figure 1C; \( n=15 \), \( P=0.03 \)).

In the previous phase 3 trial, HDC/IL-2 was reported to prevent late rather than early hematological relapse; this trend was evident in normal karyotype AML, in which few patients relapsed beyond 6-9 months after commencing immunotherapy.\(^8\) The registry data aligned with these previous findings in that HDC/IL-2 tended to prevent late but not early molecular relapse. There were thus no molecular relapses among HDC/IL-2-treated
patients with NPM1-mutated AML beyond 6 months vs. 64% late molecular relapses among matched controls (Figure 1D; n=22, P=0.009). These results support that HDC/IL-2 may exert anti-leukemic efficacy in younger AML patients with NPM1-mutated leukemia, including AML of myelomonocytic/monocytic morphology. The favorable outcome in the HDC/IL-2 arm was achieved despite that HDC/IL-2-treated patients had received fewer cycles of intensive chemotherapy than their matched controls.

NPM1 mutations accumulate in patients with normal karyotype AML. Within the group of registry patients with NPM1-mutated AML receiving HDC/IL-2, 8/9 evaluable patients had AML of normal karyotype, 4/8 were classified as low risk, and 4/8 as intermediate risk (co-mutated FLT3-ITD, n=3; aberrant karyotype, n=1). In contrast to other prevalent mutations such as mutated FLT3 or CEBPA, NPM1 mutations also accumulate in FAB class M4/M5 AML.12–14 To capture the best available comparator to the registry results, we mined the previous phase 3 database for patients with normal karyotype FAB class M4/M5 AML randomly assigned to receive HDC/IL-2 or standard of care (control). In the phase 3 trial, there was a significant benefit of HDC/IL-2 in terms of LFS and OS in this subgroup (Figure 2).

The small sample size and the inherently exploratory nature of these results should be emphasized, and further studies are required to define the benefit of HDC/IL-2 in distinct subgroups of AML. With these reservations, the results point towards anti-leukemic efficacy of HDC/IL-2 in NPM1-mutated AML and in AML of myelomonocytic/monocytic morphology.

Footnote

*Köln, #12-111, approval date Oct. 22, 2013; Ulm, #207-12, approval date Aug. 08, 2012; Wien, #1384/2013, approval date Jun. 10, 2013.
References


### Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>HDC/IL-2; n = 14</th>
<th>Matched controls; n = 21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>8 (57%)</td>
<td>10 (48%)</td>
</tr>
<tr>
<td>Women</td>
<td>6 (43%)</td>
<td>11 (52%)</td>
</tr>
<tr>
<td><strong>Age, y, median (range)</strong></td>
<td>45 (19-59)</td>
<td>46 (23-60)</td>
</tr>
<tr>
<td><strong>NPM1&lt;sup&gt;mut&lt;/sup&gt;</strong></td>
<td>10 (71%)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>15 (71%)</td>
</tr>
<tr>
<td><strong>CBF AML&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td>4 (29%)</td>
<td>6 (29%)</td>
</tr>
<tr>
<td><strong>FAB class</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>5 (36%)</td>
<td>7 (33%)</td>
</tr>
<tr>
<td>M4/M5</td>
<td>9 (64%)</td>
<td>13 (62%)</td>
</tr>
<tr>
<td><strong>Prior induction cycles, median (mean)</strong></td>
<td>1 (1.1)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>2 (1.7)&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Prior consolidation cycles, median (mean)</strong></td>
<td>1 (1.6)&lt;sup&gt;g,h&lt;/sup&gt;</td>
<td>3 (3.2)&lt;sup&gt;g,h&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> Histamine dihydrochloride/low-dose interleukin-2  
<sup>b</sup> Core binding factor AML  
<sup>c</sup> Including FLT3-ITD (n=4; 29%)  
<sup>d</sup> S-HAM (sequential high-dose cytarabine and mitoxantrone; 71%), TAD-9/S-HAM (thioguanine, cytarabine, and daunorubicin/S-HAM; 7%), or 3+5+7 (21%) induction chemotherapy. For further information, see Braess et al<sup>11</sup>.  
<sup>e</sup> TAD-9 (thioguanine, cytarabine, and daunorubicin; 79%) or high-dose cytarabine (HD-AraC; 21%).  
<sup>f</sup> Six control patients (29%) received one induction cycle with S-HAM. The remaining 15 patients (71%) received double induction with TAD followed by HAM on day 21. For further detail, see Braess et al<sup>11</sup>.  
<sup>g</sup> TAD-9 consolidation treatment. For further information, see Braess et al<sup>11</sup>.  
<sup>h</sup> Four HDC/IL-2 patients (29%) and six control patients (29%) also received low-dose maintenance chemotherapy.
Figure legends

**Figure 1. Efficacy of histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for prevention of molecular relapse in AML in a registry analysis.**

Analysis of the impact of HDC/IL-2 on switch from minimal/measurable residual disease (MRD) negativity to positivity (“molecular relapse”) in (A) all patients in the registry, (B) patients with *NPM1*-mutated AML, and (C) patients with *NPM1*-mutated myelomonocytic/monocytic (FAB class M4/M5) AML. (D) Impact of HDC/IL-2 on late molecular relapse (occurring later than 6 months after the end of chemotherapy) in patients with *NPM1*-mutated AML. HR = Hazard ratio. Statistics by the log-rank test.

**Figure 2. Efficacy of histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for relapse prevention in patients with normal karyotype M4/M5 AML.**

*Post-hoc* analysis of the impact of HDC/IL-2 on leukemia-free survival (LFS) and overall survival (OS) in patients with normal karyotype (devoid of chromosomal aberrations) myelomonocytic/monocytic (FAB class M4/M5) AML in the phase 3 trial. Patients were in first complete remission (CR1) and below 60 years of age. HR = Hazard ratio. Statistics by the log-rank test.
A Normal karyotype M4/M5 AML

Leukemia-free survival

P = 0.009
HR = 0.10

HDC/IL-2 (n=10)
Control (n=12)

Time from random assignment (years)

B Normal karyotype M4/M5 AML

Overall survival

P = 0.01
HR = 0

HDC/IL-2 (n=10)
Control (n=12)

Time from random assignment (years)